ILPIP Antibody
Code | Size | Price |
---|
PSI-3201-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-3201-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
ILPIP Antibody: PAPK, ILPIP, ILPIPA, ALS2CR2, CALS-21, PRO1038, STE20-related kinase adapter protein beta, Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 2 protein, STRAD beta
Application Note:
ILPIP antibody can be used for the detection of ILPIP by Western blot at 0.5 to 2 μg/mL. Aa 34 kDa band can be detected. Antibody can also be used for immunohistochemistry starting at 5 μg/mL.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Background:
ILPIP Antibody: ILPIP (ILP-interacting protein) has recently been shown to interact with XIAP, a member of the IAP (Inhibitor of Apoptosis) protein family. Together, these two proteins synergistically activate the TAK1/JNK1 signal transduction pathway, which acts to protect against the interleukin-1β converting enzyme of Fas-induced apotosis. This protein was independently isolated and characterized as polyploidy-associated protein kinase (PAPK), a member of the Ste20/germinal center kinase family that modulates cytoskeletal organization and cell survival, suggesting that its protective role may be a function of its kinase activity. Although two mRNA sequences have been isolated, only the shorter isoform has been observed.
Background References:
- Sanna MG, Correia JS, Luo Y, et al. (2002) ILPIP, a novel anti-apototic protein that enhances XIAP-mediated activation of JNK and protection of apoptosis. J. Biol. Chem. 277:30454-62.
- Sanna MG, Duckett CS, Richter BW, et al. (1998) Selective activation of JNK1 is necessary for the anti-apototic activity of hILP. Proc. Natl. Acad. Sci USA 95:6015-20.
- Nishigaki K, Thompson D, Yugawa T, et al. (2003) Identification and characterization of a novel Ste20/germinal center kinase-related kinase, polyploidy-associated protein kinase. J. Biol. Chem. 278:13520-30.
Buffer:
ILPIP Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Mouse: (73%)
Immunogen:
ILPIP antibody was raised against a synthetic peptide corresponding to amino acids at the C-terminus of human ILPIP.
The immunogen is located within the last 50 amino acids of ILPIP.
The immunogen is located within the last 50 amino acids of ILPIP.
NCBI Gene ID #:
55437
NCBI Official Name:
STE20-related kinase adaptor beta
NCBI Official Symbol:
STRADB
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_061041
Protein GI Number:
13027388
Purification:
ILPIP Antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis
SPECIFICITY:
Anti-ILPIP is specific for human ILPIP only.
Swissprot #:
Q9C0K7
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
Product Name | Product Code | Supplier | ILPIP Peptide | PSI-3201P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|